HOME >> BIOLOGY >> NEWS
Signal for inflammation linked to Ras-induced tumor growth

Cancer progression is dependent on the ability of tumor cells to interact with and favorably influence their environment. For instance, if a tumor is going expand, it is absolutely critical that new blood vessels are formed so that an adequate blood supply is in place to feed the growing tissue. A new research study published in the November issue of Cancer Cell demonstrates that a cytokine, a chemical signal that stimulates inflammation, plays a critical role in the initiation of new vasculature formation required to promote tumor progression.

Previous research has suggested that there may be a link between cancer-associated angiogenesis and inflammation. The protooncogene Ras has also been implicated in tumor-driven blood vessel generation. Ras is abnormally activated in nearly one quarter of all human cancers and is involved in many aspects of tumor progression, including interactions between tumor cells and the surrounding environment. However, the mechanisms that underlie these interactions are unclear.

Dr. Dafna Bar-Sagi from the Department of Molecular Genetics and Microbiology at the State University of New York at Stony Brook examined whether Ras-mediated induction of the inflammatory mediator CXCL-8 was required for tumor growth and angiogenesis in a mouse model. The researchers found that CXCL-8 production was required for Ras-stimulated tumor inflammation, vascularization, and growth. In addition, inhibition of CXCL-8 function in tumors expressing Ras led to a marked decrease in tumor angiogenesis.

Molecules that modulate CXCL-8 expression are known targets of the Ras signaling pathway, establishing a physiological link between these signaling molecules. The researchers conclude that in response to Ras activation, proinflammatory cytokines such as CXCL-8 may recruit immune cells and endothelial cells to tumor sites, representing a new mechanism for cancer-driven blood vessel generation. According to Dr. Bar-Sagi, "Our findin
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
15-Nov-2004


Page: 1 2

Related biology news :

1. Signaling for cartilage
2. Funnel in the eye: Signal focusing increases photosensitivity
3. Signaling proteins may represent biomarkers for melanoma
4. Signaling protein builds bigger, better bones in mice
5. Penn researchers discover how key protein stops inflammation
6. Gene variations directly link inflammation to an increased risk for lung cancer
7. p53 gene mutations and inflammation trigger skin cancer
8. Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation
9. Hot on the TRAIL of controlling inflammation in bacterial meningitis
10. NIAID supports research into etiology of fungal-induced inflammation in chronic sinusitis
11. Omega-3 fatty acids affect risk of depression, inflammation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology:
Cached News: